Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply

Affiliations

¹ IBD Center, Humanitas Clinical and Research Center - IRCCS, and Humanitas University, Department of Biomedical Sciences, Milan, Italy.
² Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, ACT, Australia.
³ Gastroenterology Unit, University of the Free State, Bloemfontein, South Africa.
⁴ Takeda Pharmaceuticals International AG, Zurich, Switzerland.

Editorial

Silvio Danese et al. Aliment Pharmacol Ther. 2021 Feb.

. 2021 Feb;53(3):445-446.

doi: 10.1111/apt.16227.

¹ IBD Center, Humanitas Clinical and Research Center - IRCCS, and Humanitas University, Department of Biomedical Sciences, Milan, Italy.
² Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, ACT, Australia.
³ Gastroenterology Unit, University of the Free State, Bloemfontein, South Africa.
⁴ Takeda Pharmaceuticals International AG, Zurich, Switzerland.

No abstract available

Comment on

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Danese S, et al. Aliment Pharmacol Ther. 2021 Jan;53(2):265-272. doi: 10.1111/apt.16160. Epub 2020 Nov 18. Aliment Pharmacol Ther. 2021. PMID: 33210333 Free PMC article. Clinical Trial.
Editorial: vedolizumab in inflammatory bowel diseases-less is more?
Townsend T, Subramanian S. Townsend T, et al. Aliment Pharmacol Ther. 2021 Feb;53(3):443-444. doi: 10.1111/apt.16191. Aliment Pharmacol Ther. 2021. PMID: 33428250 No abstract available.

1. Townsend T, Subramanian S. Editorial: vedolizumab in inflammatory bowel diseases-less is more? Aliment Pharmacol Ther. 2021;53:443-444.
1. Danese S, Subramaniam K, Van Zyl J, et al. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther. 2020;53:265-272.
1. Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and α4β7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:697-705. e7.
1. Samaan MA, Birdi S, Morales MS, et al. Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. Frontline Gastroenterol. 2019;11:188-193.
1. Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn's disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:838-846.e2.